Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors had a lower risk for rheumatic disease ...

How therapeutic advances can address all 3 conditions was the topic of a symposium Friday during the 81st Scientific Sessions of the American Diabetes Association (ADA), “The Intersection of Diabetes, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Prescriptions for GLP-1 receptor agonists and SGLT2 ...

Semaglutide, a GLP-1 receptor agonist (RA), was associated with a significantly lower risk for adult-onset epilepsy in patients with diabetes than other glucose-lowering drugs (GLDs). Notably, this ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a nationwide cross-sectional analysis found. From 2010 to 2023, the percentage ...

In a recent study published in the European Heart Journal, researchers assessed the impact of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors on type 2 diabetes and heart failure (HF) ...

Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed. The combined 12-month risk for myocardial infarction (MI), ...

The new report compared the benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors with those of other glucose-lowering drugs and found lower rates of heart disease and mortality. A new ...

In addition to lowering blood sugar levels, diabetes drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors can provide kidney- and cardiovascular-related benefits for people with type 2 ...

Catharine Scott-Moncrieff, DVM, PhD, explains when she prescribes insulin versus SGLT2 inhibitors, how to monitor for ketosis, and which factors most influence diabetic remission in cats.